通化東寶(600867.SH):擬投資設立杭州創新藥研發中心
格隆匯 1 月 21日丨通化東寶(600867.SH)公佈,根據公司創新藥研發戰略規劃和業務發展需要,為進一步提高公司的創新藥研發能力和市場競爭力,吸引高層次科研人才,公司擬在杭州投資設立全資子公司杭州東寶醫藥科技有限公司(暫定名,最終以市場監督管理局核准登記的名稱為準),作為通化東寶創新藥研發中心。研發中心的設立,有利於公司藉助杭州及周邊地區的區位優勢、高校資源、優惠政策等有利條件,進一步增強公司的研發競爭力,為中長期發展打下更堅實基礎。
公司現有的位於總部吉林通化的研發團隊將繼續專注於胰島素類似物、GLP-1、口服降糖藥等管線產品的研發,新設立的全資子公司將主要定位於糖尿病及其他內分泌重要領域創新藥物、創新劑型產品的儲備和研發,並與位於北京的臨牀醫學團隊和註冊團隊形成良好配合和互補,為公司建立更加有深度和有競爭力的產品管線,進一步增強公司在創新藥領域研發的綜合實力,優化公司的產業和區位佈局,符合公司長期發展戰略規劃。
杭州創新藥研發中心未來擬通過自研和對外合作相結合的方式,建立創新藥物產品管線。未來五年研發投入內的投資估算規模約為5-10億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.